Why is Akero Therapeutics (AKRO) stock gaining attention today?

September 13, 2022 07:07 AM PDT | By Rupam Roy
Follow us on Google News:


  • The AKRO stock gained more than 129 per cent on September 13.
  • Its trading volume was more than 17 million on Tuesday morning.
  • Akero Therapeutics had a market cap of about US$ 1.02 billion.

The Akero Therapeutics, Inc. (NASDAQ: AKRO) stock notched a place among the top movers in pre-market and morning trading on September 13.

The price of the AKRO stock rocketed more than 129 per cent in the morning trading on Tuesday after closing at over four per cent up in the prior session, suggesting that the investors have turned their focus to the stock.

So what could have spurred the rally in the AKRO stock on Tuesday? Let's explore with Kalkine Media®.

Why is it rising?

The market participants appear to have lauded the clinical-stage biotechnology firm's recent release about its Phase 2b HARMONY study.

The California-based company unveiled its topline data from a Phase 2b study. The study was continued for 24 weeks to assess the potential and safety measures of efruxifermin (EFX).

Notably, efruxifermin (EFX) is its lead product candidate, which was utilized on patients with NASH or nonalcoholic steatohepatitis.

According to the announcement, both the 50 mg and 28 mg dose groups of its lead product candidate fulfil the primary endpoint with 41 per cent and 39 per cent of EFX-treated patients, respectively.

The study showed that the patients had experienced at least a single stage of liver fibrosis improvement, and no worsening of NASH was seen by the final week.

Source: ©Kalkine Media®; © Canva via Canva.com

Bottom Line

The AKRO stock was priced at US$ 28.135 at 9:45 am ET on September 13, an increase of 129.30 per cent from its previous close of US$ 12.27. Its price closed at 4.78 per cent higher in the last session.

Meanwhile, more than 17.13 million shares of AKRO have been exchanged at the time of writing. During pre-market hours, its price soared to give it a market cap of about US$ 848 million, while at its trading price during writing, its market cap rose to US$ 1.02 billion.

At its current trading price, it was up by nearly two per cent YoY while soaring more than 20 per cent YTD. On a QTD basis, the AKRO stock showed over 170 per cent gains.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Top Listed Companies